Emperra

Fighting the diabetes pandemic with a telemedicine solution

Quick Facts

Type of Investment: Profit participation certificates
Venture Category Digital Health
Type of Shares Series C
Business Phase Sales Expansion

+ Profit-sharing after successful sale by auction

The ESYSTA ecosystem

Emperra has created a digital, holistic diabetes solution for the best possible management of diabetes data. It’s easy to use for patients and medical personnel alike, records all important data, and makes that data and distilled information accessible for treatment – 24/7, digital, everywhere.

Smart devices register all important treatment data. Since manual diary entries are no longer necessary, the patients can focus on their therapy. The ESYSTA technology combines and processes the data and makes them available for the patient and simultaneously to the responsible physician or diabetologist in charge.

Thanks to reliable data, successful treatment is no longer a gamble. It is scientifically proven that Emperra diabetes management can reduce the risk of serious and costly secondary diseases. And there is also proof that this technology reduces the financial burden on the healthcare sector as well as society as a whole.

The ecosystem as the backbone is currently being developed into a diabetes management platform to pool internal and external partners’ expertise and to intelligently compile existing offers and supplements while coordinating and improving them with the aim of optimizing current care concepts.

Why invest in Emperra?

Emperra is a global pioneer of digital diabetes management solutions for the recording, monitoring and evaluation of diabetes treatment.

Note: Our investment calculator is a non-binding promotional tool and does not claim to be complete. It constitutes neither investment advice nor an offer within the meaning of the statutory provisions.

€129,948.15 (18,65% p.a.) €49,720.17 (22,20% p.a.) 1 15 8 Years Total loss €33,894.72 (8,48% p.a.) €23,229.02 (11,11% p.a.) Total loss 1 8 15 Years Total loss Total loss Total loss 15 8 Years 1 Investment € 10,000 *according to the performance scenario in the Basic Information on the securities issue (PRIIP KID). The figures shown include all the costs of the product itself and include assumed costs of your advisor or distributor. Advertisement – This advertisement is based on a securities prospectus Stress scenario / Unfavourable scenario Moderate scenario Favourable scenario Emperra performance scenarios*
Total loss Total loss Total loss 1 15 8 Years €129,948.15 (18,65% p.a.) €49,720.17 (22,20% p.a) 1 15 8 Years Total loss €33,894.72 (8,48% p.a.) €23,229.02 (11,11% p.a.) Total loss 1 15 8 Years Investment € 10,000 Stress scenario / Unfavourable scenario Moderate scenario Favourable scenario *according to the performance scenario n the Basic Information on the securities issue (PRIIP KID).The figures shown include all the costs of the product itself and include assumed costs of your advisor or distributor. Advertisement – This advertisement is based based on a securities prospectus Emperra performance scenarios*


Emperra Team

Dr. med. Janko Schildt

CEO & Founder

LinkedIn

One of the founders of Emperra E-Health Technologies GmbH. Janko is in charge of the scientific development and improvement of ESYSTA. He has a PhD in medicine and has published numerous essays in the field of e-health.

Jens-Florian Krieg

CFO & CCO

LinkedIn

The team all-rounder with a focus on finance has a Diploma in Economics and has experience in finance, general management, investor relations, marketing, procurement, logistics and operations. He has worked with SMEs and tech-startups in the USA, Australia, China & other Asian countries.

Dr. med. Markus Bentrup

CDO

LinkedIn

As Head of Product Development, Markus played a decisive role in establishing Emperra’s quality management system and was responsible for bringing the product portfolio to market. He has a degree in medicine and a PhD in cell physiology.

Advisory Board

Dr. Klaus Stöckemann

Chairman – Peppermint VenturePartners

LinkedIn

Managing Director & Co-Founder at Peppermint VenturePartners. Former Partner at 3i plc and Senior Manager Office of Technology/Business Development at Schering AG

Bent Johnsen

Industry Expert – Novo Nordisk

LinkedIn

Senior Advisor at Novo Nordisk

Dr. Fred Schaebsdau – Abbott, Dexcom, Roche

Industry Expert

LinkedIn

SVP Global Strategy and Strategic Alliances at Nemaura Medical Inc. Former General Manager at Dexcom, Head of Global Strategy and Business Development at Roche and Senior Director at Abbott Laboratories

Dr. Angelika Vlachou – ILB

Venture Capitalist

LinkedIn

Senior Investment Manager at Brandenburg Kapital GmbH

Steven Anderson – CEO GPE Group

MedTech & Health Expert

Vice President Sales and Marketing S,A,G at Cardinal Health GmbH

the diabetes pandemicoffers a solution for
ESYSTAoffers a solution for the diabetes pandemic

Download all EMPERRA investment teaser now!


    By clicking on ‘Send me the teaser now’, you agree to receive the newsletter with information on, for example, our services, our company as well as to its analysis through individual measurement, storage and evaluation of opening rates and click rates in recipient profiles for the purpose of designing future newsletters according to the interests of our readers. Consent can be revoked with effect for the future. Detailed information is available in our data privacy terms.

    Aescuvest – Invest in Health

    Invest in Emperra today on aescuvest.eu, a leading pan-European investment platform in the healthcare market. At aescuvest.eu you can invest in innovative healthcare companies and start-ups through profit participation certificates.

    1

    Register for free
    All you need is an e-mail address.

    2

    Choose your company
    Choose the company you want to invest in among the Investment opportunities.

    3

    Choose an amount
    Enter how much you want to invest in the company. There are no extra costs on your investment.
    Minimum investment: 500 €

    4

    Add your personal details
    Confirm your e-mail address and provide your personal and bank details.

    5

    Verify your identity
    For security reasons, we need your ID photo. This helps us keep your investment safe.

    6

    Pay for your investment
    Send your money and that’s it! We’ll handle the rest. Let your money work for you!

    Be the first to find out about new investment opportunities and exclusive bonus promotions.

    By clicking on ‘Submit’, you agree to receive the newsletter with information on, for example, our services, our company as well as to its analysis through individual measurement, storage and evaluation of opening rates and click rates in recipient profiles for the purpose of designing future newsletters according to the interests of our readers. Consent can be revoked with effect for the future. Detailed information is available in our data privacy terms.

    Access to documents with Aescuvest Login.

    Download for registered users

    Please   Register   Please visit our Aescuvest backend to download the documents. If you already have an account, please click here   Login

    Emperra GmbH E-Health Technologies Contact & Legal Notice

    Emperra GmbH E-Health Technologies
    Zeppelinstraße 48a
    14471 Potsdam
    Germany

    Commercial Register: HRB 27562 P
    Registered Office: Potsdam
    Year of Incorporation: 2008
    Managing Director: Dr. med. Janko Schildt

    Additional information documents, in particular the securities prospectus regarding your investment, which contains, among other things, risk warnings, the Terms and Conditions of the Profit Participation Certificates as well as corporate documents and a description of both the Issuer and the Target, the legally required „Information for Consumers“ and the legally required revocation instructions can also be found on our website under the following link: dcii.investinhealth.eu